MedTrace Logo

Catheter Ablation Therapy for Persistent Atrial Fibrillation

NCT02892162 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2016-09-20

No results posted yet for this study

Summary

Use of catheter ablation for persistent atrial fibrillation (PerAF) remains controversial due to unsatisfactory long-term success rates (15% - 28.4%). The investigators' previous study indicated that the upper area of the left atrium (LA) plays an important role in PerAF, with the LA roof and mitral isthmus appearing to serve as main substrate in progression from PAF to PerAF and maintenance of fibrillatory activities. The investigators therefore hypothesized that AF should not be initiated or sustained if the latter crucial regions for AF maintenance are abolished. This study aimed to describe the efficacy and safety of additional linear ablation on the left atrial anterior wall for PerAF.

Conditions

  • Persistent Atrial Fibrillation

Interventions

PROCEDURE

Additional LAAW linear ablation

Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.

Sponsors & Collaborators

  • Beijing Hospital

    collaborator OTHER_GOV

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • Wuhan Asia Heart Hospital

    collaborator OTHER

  • First Affiliated Hospital of Kunming Medical University

    collaborator OTHER

  • China National Center for Cardiovascular Diseases

    lead OTHER_GOV

Principal Investigators

  • Yan Yao, MD,PhD · China National Center for Cardiovascular Diseases

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-07-31
Completion
2019-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02892162 on ClinicalTrials.gov